SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
HASBROUCK HEIGHTS, N.J., March 29, 2017 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. The Company is very pleased with the progress it has made, which is in line with its previous timeline announcements. The Company now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks. Nymox intends to provide fuller details at the above time.
For more information please contact [email protected] or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2015, and its Quarterly Reports.
Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com
